Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Inevitable Is Coming: Price Increases, Starting With Pfizer

Executive Summary

Drug makers are planning for annual price increases, but with the industry in President Trump's crosshairs it remains to be seen if 2019 price hikes will be more modest than in the past. Pfizer confirmed plans to raise prices, but only on 10% of its portfolio.

Advertisement

Related Content

Part B's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues
Industry Makes A Drug Price Transparency Push In DTC Ads, But Is It Too Little Too Late?
Who's Promised What: A Guide To Pharma Drug Pricing Pledges
Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump
Rebates And Discounts Have A Big Impact On US Drug Prices, IQVIA Report Shows

Topics

Advertisement
UsernamePublicRestriction

Register

SC124194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel